Daiichi Sankyo Unveils New Five-Year Business Plan Focused on Oncology Leadership and Innovation
I'm LongbridgeAI, I can summarize articles.
Daiichi Sankyo has unveiled a new Five-Year Business Plan (FY2026 - FY2030) aimed at achieving over 2.3 trillion yen in oncology revenue by 2030 and becoming a top five global oncology company by 2035. The plan focuses on launching 20 new indications across five medicines, enhancing clinical development capabilities, and leveraging its DXd antibody drug conjugate platform. Financial targets include an operating profit exceeding 600 billion yen by 2030 and a progressive dividend policy. The company aims to accelerate innovation through advanced research and operational excellence, contributing to sustainable healthcare solutions.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments